The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | P | Antiparasitic products, insecticides and repellents | |
| 2 | P01 | Antiprotozoals | |
| 3 | P01B | Antimalarials | |
| 4 | P01BF | Artemisinin and derivatives, combinations | |
| 5 | P01BF01 | Artemether and lumefantrine |
| Active Ingredient | Description | |
|---|---|---|
| Artemether and Lumefantrine |
Artemether/lumefantrine fixed-dose combination comprises a fixed ratio of 1:6 parts of artemether and lumefantrine, respectively. The site of antiparasitic action of both components is the food vacuole of the malarial parasite, where they are thought to interfere with the conversion of haem, a toxic intermediate produced during haemoglobin breakdown, to the nontoxic haemozoin, malaria pigment. Both artemether and lumefantrine have a secondary action involving inhibition of nucleic acid and protein synthesis within the malarial parasite. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| COARTEM Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RIAMET Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
